insights_auto
Kodėl „NOTA“ sumažėjo 2,76%?
Įsigilintichevron_right
NOTA:FRA
Novartis
141,00 €
arrow_downward
−2,76%(−4,00) 1 D.
11-02, 08:42:13 GMT+1 · EUR
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „NOTA“ įžvalgos...
Atidaryti
141,00 €
Aukšta
141,00 €
Žema
141,00 €
Rinkos kapitalizacija
268,29 mlrd.
Vid. kiekis
12,00
Apimtis
0,00
52 sav. aukšta
145,00 €
52 sav. žema
102,50 €
Darbuotojų skaičius
75 tūkst.
Atidaryti
141,00 €
Aukšta
141,00 €
Žema
141,00 €
Rinkos kapitalizacija
268,29 mlrd.
Vid. kiekis
12,00
Apimtis
0,00
52 sav. aukšta
145,00 €
52 sav. žema
102,50 €
Darbuotojų skaičius
75 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Investing.com
·
prieš 3 valandas
Deutsche Bank turns bearish on Novartis as shares recover failed trial losses
Investing.com
·
prieš 4 valandas
Deutsche Bank downgrades Novartis stock rating to sell on valuation
marketscreener.com
·
prieš 6 valandas
Swiss stocks - Factors to watch on November 2
Seeking Alpha
·
prieš 2 dienas
Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach (NVS)
Profilis
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Apie „Novartis“
Generalinis direktoriusVasant Narasimhan
Darbuotojai75,3 tūkst.
Įkurta1996-03-07
Pagrindinė būstinėBazelis, Bazelio miestas, Šveicarija
Sektorius-
Svetainėnovartis.com